西藏诺迪康药业股份有限公司 关于公司产品新活素被继续纳入国家医保药品目录的公告

Group 1 - The core product, recombinant human brain natriuretic peptide injection (brand name: Xinhuasuan), has been included in the National Medical Insurance Directory and adjusted to the regular category, effective January 1, 2026 [1][4] - Xinhuasuan is a first-class new biological product developed by the company, used for treating acute heart failure, improving symptoms and quality of life for patients, while also reducing hospitalization costs and duration [1][2] - The product's production and sales figures indicate strong performance, with 7.35 million units produced and 7.01 million units sold in 2024, generating revenue of 2.433 billion yuan, accounting for 86.89% of the company's main business income [3] Group 2 - The adjustment to the regular category is expected to have a positive impact on the company's future product sales and long-term development, although the specific impact on operating performance cannot yet be estimated [4]